Progress on colistin
October 27, 2014 Leave a comment
The European Medicines Agency recommended updating and harmonising the Summary of Product Characteristics of nationally approved colistin products throughout the EU to reflect what is currently known. The recommendations focus mainly on optimising dosing schedules but will also review the quality of the products and the way the potency of colistimethate sodium is measured and tested. Details here. This is a great success given the administrative challenges as the products have not been approved under the EU regulatory framework and knowledge is still evolving about how to use this drug.
In spring 2013 an expert conference in Prato summarised the current knowledge on polymyxin drugs and laid the ground for awareness and the need to update the information: The Lancet Infectious Diseases, 21 October 2014
R.L. Nation, J. Li, O. Cars, W. Couet, M.N. Dudley, K.S. Kaye, J.W. Mouton, D. L. Paterson, V. H. Tam, U. Theuretzbacher, B.T. Tsuji, J.D. Turnidge: Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.